Clinical Trial. NCT Number, Sponsor, Condition, Start Date, Phase. NCT04699188, Novartis Pharmaceuticals|. KRAS G12C Mutant Solid Tumors|Carcinoma, Non-Small- JDQ443 + tislelizumab dose escalation (Ph Ib) in KRAS G12C-mutated solid tumors. A Phase III study, KontRASt-02 (NCT05132075) of JDQ443
Opnurasib (JDQ-443) | KRAS G12C Inhibitor | MedChemExpress Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study Study Details | NCT05132075 | Study of JDQ443 in Comparison
For example, you may enter the name of a drug or the NCT number of a KRAS G12C inhibitor. Participant has EGFR-sensitizing mutation and/or ALK KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review
Opnurasib (JDQ-443) | Ras inhibitor | Mechanism | Concentration Ongoing clinical trials of RTK plus KRAS G12C inhibitor for KRAS G12C mutated colorectal cancer. Combination. NCT number. Phase. Population. Current status Study Details | NCT04699188 | Study of JDQ443 in Patients With
A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation. A summary of the published clinical trials of KRASG12C inhibitors in patients with NSCLC is presented in Table 1. Table 1. KRASG12C Inhibitors Combining EGFR and KRAS G12C Inhibitors for KRAS G12C
Abstract LBA038: KontRASt: A Phase Ib/II, open-label, multi-center Background: KRAS G12C oncogenic mutations occur in ~13% of non-small cell lung cancers (NSCLCs) and up to 4% of other solid tumors. JDQ443 For example, you may enter the name of a drug or the NCT number Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation.
Clinical Trial Information (data from https://clinicaltrials.gov, updated on KRAS G12C Mutant Solid Tumors|Carcinoma Non-Small-Cell Lung|Carcinoma Selective KRAS G12C inhibitors in non-small cell lung cancer Novartis announces early clinical data for unique KRASG12C
In the beginning of January 2021, Novartis KRAS G12C inhibitor compound JDQ443 is undergoing a phase Ib/II clinical trial as a monotherapy and